Please ensure Javascript is enabled for purposes of website accessibility

Why Gilead Sciences Shares Tumbled 18% in January

By Todd Campbell – Feb 2, 2016 at 12:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors reined in exposure ahead of the launch of a competitor's drug.

Image source: Gilead Sciences.

What: Ahead of a competitor winning approval for its competing hepatitis C therapy, shares in Gilead Sciences (GILD -0.83%) fell 18% in January, according to S&P Capital IQ.

So what: Gilead Sciences gets more than half of its revenue from the sale of hepatitis C drugs and as a result, investors reined in their exposure to the company ahead of the FDA approval of Merck & Co.'s (MRK -0.69%) Zepatier on Jan. 28.

Given Merck's therapy put up impressive cure rates and a solid safety profile in clinical trials, the FDA's decision isn't surprising.

However, Merck's decision to price its new drug at a list price of $54,600 may have shocked some investors. The price is a steep discount to the $84,000 and $94,500 that Gilead Sciences charges for its hep C drugs Sovaldi and Harvoni, respectively.

The pricing decision certainly turns up the heat on Gilead Sciences and competitor AbbVie (ABBV -1.29%), which markets the HCV drug Viekira Pak.

Now what: A price war isn't something that investors typically want, but it may not be as bad for Gilead Sciences as some fear.

The launch of Viekira Pak with a lower price in January 2015 led to Gilead Sciences matching prices to maintain market share, but revenue actually grew, rather than shrank, last year because lower prices resulted in more prescriptions being written.

Regardless, Gilead Sciences has an FDA decision coming up this June for its next-generation hepatitis C drug, and if approved, that drug could significantly limit any threat posed by Merck & Co.'s Zepatier because its efficacy and safety are arguably best in class.  

Todd Campbell owns shares of Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$86.18 (-0.69%) $0.60
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.34 (-0.83%) $0.52
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$141.21 (-1.29%) $-1.85

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.